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Cancer mortality in Europe has been decreasing since the late 1980s or 1990s though with different patterns 
in many areas. In this work, we updated trends in cancer mortality in Europe.
Methods
We extracted data from the World Health Organization mortality database for 24 cancer sites, 36 European 
countries and the European Union (EU) as a whole over the 1990-2017 period. We computed age-
standardized death rates per 100,000 population and we performed a joinpoint regression analysis for all 
cancers, selected major neoplasms and countries. The estimated annual percent change (APC) for each 
identified linear segment, and the weighted average APC (AAPC) over the entire study period were provided 
as summary measures of the changes in rates over the time period.
Results
In 2015, the age-standardized mortality rates from all cancers in the EU were 137.5 deaths per 100,000 in 
men and 85.7 in women. Eastern European countries showed the highest rates with values over 150 deaths 
per 100,000 in men and over 100 deaths per 100,000 in women. Mortality from all cancers in the EU 
declined annually by 1.5% in men since 2006 and by 0.8% in women since 2007. Most cancer sites showed 
decreasing trends with steady declines over the whole period for cancers of stomach, intestines, lung in men, 
breast and prostate. Unfavourable mortality trends persisted for cancers of liver, lung in women, pancreas, 
besides skin and kidney. 
Conclusions
The downward trends in total cancer mortality in Europe still continue over the last decade. However, the 
trends were less favourable in most eastern European countries. Tobacco control in men (but not in women), 
improvements in diagnosis and therapy were the underlying factors of these trends.
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Cancer mortality shows substantial variation across Europe. Steady declines were observed since the 1980s 
in most western European countries, and a decade later in central and eastern Europe [1]. Such favourable 
trends have been attributed to the reduced prevalence of smoking in men [2, 3] and decreased alcohol 
consumption in Mediterranean countries [4], but also to the increased availability of screening, early 
diagnosis, and treatment. However, suboptimal tobacco control, inadequate adoption of modern diagnostic 
techniques and effective treatment have produced remarkable disparities in cancer mortality across Europe 
[5] with systematically less favourable mortality trends in eastern European countries [1, 6].
In this work, we provide updated data on cancer mortality in Europe.
Materials and Methods
We extracted official death certification data from the World Health Organization (WHO) database for 24 
cancer sites plus all neoplasms in 36 European countries plus the European Union 28 Member States (EU-
28) as a whole, for the 1990-2017 period [7]. All countries considered had death certification coverage over 
95%, except Serbia (84%). During the considered calendar years, we used three different Revisions of 
International Classification of Diseases (ICD) and coded cancer deaths for all calendar years and countries, 
according to the 10th Revision of the ICD [8].
We obtained estimates of the resident population, based on official censuses, from the same WHO database 
[7]. Since population estimates for France and Ireland in 2015, Spain in 2016, and Switzerland in 2014 and 
2015 were not available in the WHO database, these were obtained from the EUROSTAT database [9]. 
No interpolations were made for missing data in a few countries and calendar years, except for the 
calculation of the rates for the EU-28 as a whole. 
Using the dataset with deaths counts and resident populations, we calculated age-specific rates for 18 age 
groups (from 0-4 to 80-84, and ≥85 years), sex and calendar year. We then computed age-standardized 
mortality rates per 100,000 person-years (at all ages and the 35-64 age-group), based on the world standard 
population [10].
For the EU-28 as a whole and a subset of 24 selected major countries (i.e. with populations over 5 million 
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major cancers (i.e. intestines, lung, breast and prostate), over the 1990-2017 period [11]. We thus identified 
the time point(s), called “joinpoints”, when a change in the linear slope (on a log scale) of the temporal trend 
occurred [12], by testing from a zero up to a maximum of four joinpoints. The estimated annual percent 
change (APC) for each identified linear segment, and the weighted average APC (AAPC) over the entire 
study period (1990–2017) as a summary measure, were computed for each joinpoint model [12, 13].
Results
Table 1 and Table 2 give the overall age-standardized mortality rates per 100,000 men and women, 
respectively, and number of deaths from selected cancers observed in 2015 in 36 European countries and the 
EU-28 as a whole. Figures S1-S8 show rates (from largest to smallest) for the EU-28 by cancer site (Figure 
S1), and for all neoplasms (S2) and selected major cancers (S3-S8) by country (Online-only Supplementary 
Material).
In men, all neoplasms mortality rate in the EU-28 was 137.5/100,000 corresponding to 760,123 deaths in 
2015. Most eastern European countries and Russia showed the highest mortality rates, while northern 
European countries had the lowest ones. With regard to major cancers, in the EU-28, male mortality rates 
were 34.8/100,000 for lung cancer, 16.1 for intestinal cancer, 10.7 for prostate cancer, 7.9 for pancreatic 
cancer, and 6.3 for stomach cancer. Mortality rates from male lung cancer ranged between 15-23/100,000 in 
Scandinavian countries, 27-36 in the UK, France, Germany, Italy and Spain, to 45-63 in eastern European 
countries and Russia. Mortality rates from intestinal cancer ranged from about 13-15/100,000 in major 
western countries, to around 30/100,000 in Hungary, Slovakia and Croatia. The Russian rate was 
18.7/100,000. Mortality from prostate cancer showed the highest rates in Baltic and Scandinavian countries, 
while the lowest ones were in Italy and other southern European countries. Mortality from pancreatic cancer 
ranged between 6.5 and 8.5/100,000 in the UK, Spain, Italy, France, and Germany, to around 10-11/100,000 
in several central and eastern European countries. Stomach cancer mortality rates ranged from 3-4 
deaths/100,000 in northern and central European countries, to 19.4/100,000 in Russia, followed by other 
eastern European countries. Portugal, Italy, and Spain had relatively high rates, too.
In women, total cancer mortality rate in the EU-28 was 85.7/100,000, corresponding to 603,984 deaths in 
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In contrast, the lowest mortality rates were observed in southern and eastern countries, with the lowest one in 
Spain. With regard to major cancers, EU-28 female mortality rates were 14.5/100,000 for breast cancer, 14.3 
for lung cancer, 9.4 for intestinal cancer, 5.5 for pancreatic cancer, and 2.9 for stomach cancer. The highest 
breast cancer rates were in Serbia and other central European countries (around 14-15), and Russia (15.7), 
while the lowest ones were in Norway, other Scandinavian countries, and Spain (about 10-11/100,000). The 
highest lung cancer rates were in Hungary, followed by some northern countries, while the lowest ones were 
in eastern Europe. Mortality rates from intestinal cancer ranged between 7-8 deaths/100,000 in Austria, 
Greece, Switzerland, and France, to 15.1/100,000 in Hungary. Mortality from pancreatic cancer ranged from 
3.6/100,000 in Ukraine, around 4 in Portugal and Spain, to 7.3 deaths/100,000 in Hungary. Mortality from 
stomach cancer ranged from 1.5/100,000 in France, followed by most western and northern European 
countries (rates around 2), to 7.9/100,000 in Russia. 
Corresponding figures for the 35-64 age group are displayed in the Tables S1 and S2 (Online-only 
Supplementary Material).
Figure 1 and Table S3 show the joinpoint regression analysis of mortality trends for 23 cancer sites plus all 
neoplasms in the EU-28 from 1990 to 2015 at all ages and for the 35-64 age group, in men and women. The 
downward trends in total cancer mortality started in the early 1990s and the mortality rate at all ages declined 
annually by 1.5% in men since 2006 and by 0.8% in women since 2007. Downward trends were observed for 
most cancer sites, with steady declines for cancers of stomach, intestines, lung in men, breast and prostate. In 
contrast, unfavourable trends were observed for lung cancer in women and increasing or stable rates were 
observed for pancreatic cancer. Favourable trends were also observed for most other cancer sites, except 
liver over the recent calendar years, skin and kidney in men. 
Figures 2a-2e (and Tables S4a-S4e) give the results from the joinpoint analysis of mortality trends (1990-
2017) for all neoplasms and major cancer sites in 24 selected countries. Mortality from all neoplasms 
declined in most countries for both sexes, with the exceptions of Bulgaria, Greece and Romania. The 
favourable trends started after the mid-1990s in most eastern countries, Norway and Spain. Upward trends 
were observed in mortality rates from intestinal cancer in East Europe. Lung cancer mortality decreased in 
most countries in men, except in Bulgaria, Portugal and Romania. Lung cancer mortality in women increased 








niversità degli Studi di M
ilano user on 31 M
ay 2019
 6
northern European countries, and around 1.5% in most western and southern countries. In Russia, breast 
cancer mortality started to decline over the last few years. Greater declines in breast cancer were observed 
among middle-aged women. After the increasing trends observed over the 1990s, mortality from prostate 
cancer declined in most countries with a few exceptions in East Europe.
Discussion
Mortality rates from major cancer sites continued to decline in the EU-28 over the 2000s, with the only 
exception of pancreatic, skin and kidney (only in men) cancers and of some increase in mortality from liver 
cancer in both sexes and lung cancer in women. However, there are substantial differences among EU 
countries, with less favourable trends taking place in some eastern European countries.
The downward trends in overall cancer mortality is mainly driven by the declines in mortality from most 
tobacco-related cancers in men consequent to the reduction in male smoking prevalence across Europe [2, 3]. 
The opposite trend in female lung cancer mortality reflects the different stage in the smoking epidemic 
between sexes, and the lagged decline in smoking prevalence in women compared to men [2, 14, 15].
The potential impact of tobacco reduction in men on mortality from pancreatic cancer was partly 
counterbalanced by the rising prevalence of obesity and diabetes over the last three decades [16]. Moreover, 
improved diagnosis and certifications may have played some role on the unfavorable mortality trend from 
pancreatic cancer. 
Apart from the smoking prevalence reduction in men, the steady decline in stomach cancer mortality could 
also be attributed to improved water sanitation, lifestyle and environmental conditions that resulted in 
reduced prevalence of Helicobacter pylori infection [17]. The reduced consumption of food preserved by 
salting, pickling and smoking may have also contributed to the downward trend [18].
Improved working conditions and less exposure to occupational carcinogens [19, 20] have also contributed 
to the downward trends in mortality from lung and bladder cancer. 
Reductions in alcohol consumption, especially in southern Europe, partly explains the decline in cancer of 
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northern Europe and increased prevalence of HCV in northern and eastern Europe [4] have driven the 
increment in primary liver cancer mortality all over Europe [21, 22]. 
Screening and early diagnosis have contributed to the reduction in mortality from colorectal cancer [23, 24]. 
However, the screening uptake differs among countries due to resource availability that may explain some of 
the between-country variability in mortality patterns and trends [25, 26].
Mammography screening programs, early diagnosis and mostly availability of effective therapy, including 
progress in radiotherapy and surgery are the key factors for the substantial downward trends in breast cancer 
mortality in Europe [27, 28], as in other (high-income) areas of the world [29]. Some eastern countries, 
including Romania, Russia and Ukraine showed less favorable trends. Breast cancer rates in those areas of 
the continent were particularly low in the past [30], and this may reflect some levelling of rates across 
Europe. In addition, delays in the adoption of effective screening programs and treatments are possible in 
those countries [6]. 
Wider adoption of radical prostatectomy in combination with adjuvant hormonal therapy for localized 
cancers may partly explain the downward trend in prostate cancer mortality observed since the late 1990s in 
Europe, though the role of PSA testing is likely, but still unquantified [31].
The decline in mortality from cancer of the testis observed since 1970s continued over the 1990s, but 
levelled off during the 2000s. This pattern has been mainly attributed to the adoption of effective treatments, 
mainly platinum-derived chemotherapy and its analogues [32].
Subsequent advancements in therapies were the key underlying factors of the downward trend in mortality 
from leukaemias, targeted therapy has improved the prognosis of patients with chronic myelogenous 
leukemia and allogeneic hematopoietic cell transplantation improved survival in all malignant hematologic 
diseases [33-36]. 
The less favorable trend in mortality from skin cancer may reflect the increased recreational exposure to 
sunlight ultraviolet radiation and use of tanning beds [37], while the growing obesity [16] and hypertension 
rates are possible explanation of the increased mortality due to kidney cancer [38].
Despite possible problems in data quality, death certification is reasonably valid in all the European countries 
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Figure 1. Joinpoint analysis of trends in age-standardized (world population) mortality rates from 23 cancer 
sites and all neoplasms (malignant and benign) in the European Union, from 1990 to 2015. Filled boxes 
represent men, all ages; empty boxes men, 35-64 age group; filled circles women, all ages; empty circles 
women, 35-64 age group.
Figure 2. Joinpoint analysis of trends in age-standardized (world population) mortality rates from all 
neoplasms (a), cancers of intestines (b), lung (c), breast (d) and prostate (e), in 24 selected European 
countries, from 1990 to 2017 (according to data availability). Filled boxes represent men, all ages; empty 
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Table 1. Overall age-standardized (world population) mortality rates (first row) and average annual number of deaths (second row) from selected cancers per 100,000 men in 36 
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Norway 2.37 3.18 3.84 16.19 2.61 0.44 7.46 0.64 22.83 0.23 0.53 4.69 15.85 0.12 3.43 3.11 0.40 0.16 3.37 2.53 3.77 110.02
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Skin Prostate Testis Bladder Kidney Thyroid HL NHL MM Leukemias
All 
neoplasms
112 160 204 864 128 24 376 34 1191 11 23 224 1045 5 215 167 19 8 187 143 186 5962
6.95 3.74 10.53 21.41 1.36 1.93 7.82 4.48 50.21 0.74 0.94 4.31 13.38 0.54 8.62 5.67 0.27 0.39 3.08 2.06 5.02 178.87Poland
2117 1167 3419 7223 436 639 2469 1405 16261 195 237 1461 4876 129 2990 1847 91 105 956 689 1528 58310
7.07 4.62 12.48 20.31 6.61 1.42 6.91 2.85 28.97 0.60 0.71 2.13 10.92 0.23 5.41 2.69 0.35 0.37 3.99 2.26 4.38 143.65Portugal
620 437 1403 2529 695 169 753 285 3041 45 65 241 1723 15 743 303 40 31 455 291 470 16299
11.74 2.90 13.81 22.21 1.34 0.70 8.79 6.39 35.48 1.22 1.04 2.81 9.56 0.48 5.80 3.98 0.43 0.77 3.12 0.56 4.05 166.01Rep. of 
Moldova 263 65 302 483 29 16 195 146 776 23 16 60 213 10 127 82 9 16 60 12 81 3569
12.17 3.53 12.34 19.49 3.24 1.28 9.03 5.93 47.80 1.56 0.74 2.65 10.02 0.46 6.12 3.45 0.34 0.43 2.46 1.11 4.74 175.29Romania
1869 572 2230 3691 543 240 1578 963 8058 235 107 489 2198 61 1211 595 60 63 386 205 763 30439
8.33 5.69 19.38 18.74 5.48 . 8.81 4.39 44.71 . . 1.76 11.77 . 5.46 . . . 2.40 1.09 4.53 169.76Russia
7622 5242 17960 17476 4974 . 8095 4022 41123 . . 1601 11111 . 5144 . . . 2092 968 3633 155002
6.22 3.17 7.90 21.92 1.90 1.75 8.44 4.89 55.22 0.93 1.19 4.27 12.11 0.93 7.02 4.03 0.49 0.85 2.53 1.57 5.04 177.28Serbia
404 212 587 1648 133 130 618 337 3815 62 56 301 1073 40 546 275 33 43 173 115 319 12660
13.75 6.11 8.94 28.39 3.70 2.84 10.33 3.87 38.71 0.71 1.12 3.96 16.75 0.67 6.54 7.00 0.27 0.59 4.59 2.24 5.18 186.29Slovakia
554 251 371 1194 153 120 428 156 1607 25 41 161 738 23 283 282 11 23 188 94 202 7671
6.46 3.47 9.58 21.48 7.24 1.75 8.92 1.95 39.96 0.30 1.39 3.84 15.78 0.45 5.10 6.12 0.34 0.19 4.67 2.20 5.79 161.33Slovenia
122 72 211 467 156 40 185 41 836 6 18 83 404 6 129 129 8 4 100 50 114 3475
4.04 3.65 6.35 17.32 6.50 1.06 6.90 2.58 36.43 0.70 0.78 1.70 8.25 0.14 6.25 4.67 0.26 0.27 2.86 1.66 4.04 132.56Spain
1733 1626 3331 9552 3064 606 3311 1228 17259 194 309 931 5757 44 3860 2418 133 122 1467 976 2002 67841
2.19 3.03 3.10 13.37 2.37 1.72 7.60 0.42 15.48 0.22 1.12 3.35 15.69 0.10 3.55 3.37 0.26 0.15 2.83 2.09 3.49 101.96Sweden
221 331 348 1611 253 193 872 48 1813 20 98 363 2357 7 477 387 30 17 341 264 393 12241
3.69 4.06 3.82 11.40 5.62 0.86 7.03 0.81 23.97 0.33 1.08 3.02 11.97 0.33 3.82 3.22 0.37 0.25 2.78 2.23 3.70 107.68Switzerland
293 343 332 1072 484 78 605 65 2056 21 73 278 1356 19 403 307 33 22 274 217 345 9845
10.73 4.74 14.40 17.92 3.21 . 7.88 4.56 34.07 . . 1.88 10.91 . 5.13 . . . 2.46 0.89 4.71 149.07Ukraine
3111 1390 4389 5653 925 . 2356 1331 10264 . . 544 3644 . 1644 . . . 670 263 1207 44518
3.26 8.18 3.84 14.92 4.19 0.44 6.48 1.04 26.88 0.47 0.88 2.86 13.25 0.18 4.31 4.05 0.22 0.32 3.76 2.22 3.91 124.32UK
1927 5466 2817 10880 2875 332 4469 698 19200 207 487 1962 11827 71 3681 2796 153 188 2718 1725 2734 89773
3.13 8.04 3.79 14.66 4.02 0.44 6.48 0.95 25.97 0.47 0.88 2.87 13.17 0.15 4.26 3.97 0.23 0.32 3.71 2.17 3.87 122.02UK, Engl and 
Wales 1639 4793 2483 9559 2447 297 3988 574 16574 179 430 1746 10580 55 3265 2443 139 164 2406 1505 2429 78821
5.31 7.46 4.04 16.03 4.79 0.39 6.43 1.45 30.64 0.64 0.98 3.31 12.08 0.48 4.22 4.78 0.09 0.32 4.32 2.66 5.52 134.76UK, Northern 
Ireland 84 121 72 287 87 6 116 24 551 8 15 60 262 5 87 89 3 6 77 52 78 2415
3.97 9.90 4.35 17.38 5.88 0.47 6.47 1.75 35.37 0.49 0.89 2.67 14.40 0.32 4.88 4.69 0.18 0.33 4.13 2.60 3.79 145.16UK, Scotland
204 552 262 1034 341 29 365 100 2075 20 42 156 985 11 329 264 11 18 235 168 227 8537
5.03 4.58 6.28 16.06 4.80 1.24 7.91 2.13 34.83 0.59 0.91 2.54 10.71 0.29 4.99 4.72 0.27 0.32 3.36 1.89 4.39 137.53EU-28
22892 23128 34666 93241 25602 7263 42462 10667 183943 2197 3877 14009 74998 946 31938 26447 1478 1439 18802 11380 23713 760123
 aAvailable year for Russia and Macedonia: 2013; for Belarus, Bulgaria and Slovakia: 2014.
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Table 2. Overall age-standardized (world population) mortality rates (first row) and average annual number of deaths (second row) from selected cancers per 100,000 women in 36 









Skin Breast Uterus Ovary Bladder Kidney
Thyr
oid HL NHL MM Leukemias
All 
neoplasms






















1.40 0.66 2.74 6.78 2.08 1.02 6.18 0.21 15.04 0.26 0.83 1.62 13.81 3.83 4.18 0.90 1.69 0.23 0.15 1.92 1.31 2.52 81.76Austria
153 67 363 973 242 148 805 21 1493 14 61 201 1568 413 465 152 246 36 15 273 175 332 9755
0.96 0.38 6.60 9.38 1.15 . 3.73 0.04 3.11 . . 1.37 11.87 7.30 4.74 0.33 . . . 1.39 1.19 2.40 71.34Belarus
88 40 719 1107 114 . 409 5 339 . . 122 1106 647 422 49 . . . 152 123 253 7171
1.29 1.38 1.59 8.56 1.75 0.46 5.42 0.18 15.68 0.35 0.67 1.48 15.25 3.59 4.62 1.20 1.53 0.30 0.13 1.94 1.22 2.91 83.45Belgium
162 201 268 1541 270 95 895 26 1936 41 87 219 2167 524 669 252 253 46 18 374 229 507 12750
1.22 0.36 4.46 10.08 1.24 0.90 5.16 0.38 8.86 0.63 0.09 1.15 16.11 9.78 5.27 1.40 1.05 0.26 0.62 1.54 0.62 1.93 87.02Bulgaria
92 28 441 1095 124 94 520 32 739 43 11 119 1343 726 416 143 93 28 29 118 58 175 7575
1.45 0.72 4.98 13.31 1.74 1.98 6.54 0.21 14.01 0.68 0.81 2.29 18.14 6.34 5.88 1.66 1.91 0.22 0.23 2.57 1.56 3.42 103.10Croatia
68 40 323 889 96 142 399 12 720 32 17 152 1038 346 322 131 135 16 9 173 98 183 6122
1.63 0.65 3.29 10.69 1.02 2.70 6.70 0.21 13.25 0.40 0.75 1.67 12.35 6.13 6.28 1.39 2.93 0.28 0.22 1.81 1.41 2.53 90.36Czech Republic
190 83 450 1613 144 404 982 27 1693 26 65 245 1609 753 736 242 419 43 29 272 203 370 12311
1.59 1.26 1.88 11.60 1.84 0.93 6.36 0.24 25.63 0.21 0.65 1.80 14.83 3.75 5.29 1.67 1.68 0.32 0.15 1.38 1.23 2.76 100.65Denmark
99 97 131 935 130 62 480 14 1788 12 31 132 1069 259 368 144 133 26 12 125 111 221 7430
0.94 0.52 6.24 11.20 1.69 1.57 5.46 0.10 9.02 0.77 2.14 1.83 13.74 7.19 5.58 0.97 2.87 0.91 0.15 2.16 2.13 2.98 90.65Estonia
16 10 127 261 36 37 128 2 166 5 5 55 240 115 106 26 82 20 2 54 42 70 1826
0.95 1.10 2.10 7.58 2.04 1.40 6.53 0.06 10.27 0.17 0.80 1.18 11.86 3.23 5.64 0.69 1.87 0.34 0.10 2.84 1.57 2.02 72.54Finland
74 89 169 663 186 139 545 4 771 13 34 100 813 247 411 74 171 34 10 263 139 166 5798
1.18 0.95 1.54 7.97 1.84 0.51 5.26 0.23 12.34 0.33 0.60 1.19 14.54 3.96 4.00 0.93 1.60 0.20 0.12 1.80 1.25 2.44 76.03France
909 865 1536 9074 1793 625 5339 156 9055 226 461 1130 12233 3395 3458 1202 1683 232 95 2072 1494 2625 71313
1.29 1.00 2.77 8.33 1.74 1.39 6.26 0.21 15.18 0.23 0.74 1.32 15.45 3.71 4.69 1.08 2.28 0.28 0.12 1.91 0.93 2.65 85.01Germany
1378 1238 3829 12572 2126 2090 8659 205 15881 168 690 1637 18136 4143 5573 1872 3362 416 132 2915 1280 3579 107396
0.70 0.21 2.94 7.02 1.15 0.42 4.91 0.18 10.35 0.37 0.69 1.08 13.60 3.55 4.21 0.97 1.08 0.29 0.29 1.32 1.25 2.99 72.63Greece
121 29 515 1402 178 81 848 29 1413 49 75 173 2117 499 562 228 199 52 46 218 246 513 11833
2.91 0.90 4.55 15.08 0.67 2.39 7.28 0.74 29.42 0.25 1.20 1.55 17.88 8.02 6.13 1.88 2.04 0.35 0.26 2.20 1.24 4.21 122.80Hungary
305 113 647 2229 82 365 1032 74 3397 12 79 225 2220 883 728 280 294 55 22 285 167 470 15443
0.39 0.97 2.60 9.87 2.43 1.15 7.05 . 22.08 . 1.04 0.51 18.07 2.69 4.41 0.73 1.05 0.29 0.15 2.21 0.53 1.30 89.16Iceland
2 5 12 32 9 5 28 . 69 . 3 2 55 7 15 3 6 2 1 6 3 4 299
0.97 2.62 2.66 9.59 2.07 0.79 5.25 0.21 17.80 0.25 0.39 1.60 16.67 5.94 6.49 1.35 1.74 0.39 0.24 2.61 1.62 2.21 94.23Ireland
46 132 135 471 90 43 250 9 785 8 18 90 678 231 267 71 89 19 11 127 82 105 4241
1.03 0.48 3.52 8.97 1.88 1.49 5.49 0.17 10.71 0.36 0.60 1.24 14.12 3.55 3.94 0.88 1.37 0.29 0.25 2.11 1.46 2.73 80.02Italy
990 485 3933 10450 2043 1777 5945 161 9570 200 407 1197 12312 2969 3269 1214 1470 331 170 2234 1688 2629 79500
1.39 0.88 6.43 11.22 1.15 0.84 5.69 0.04 7.68 0.50 0.78 2.54 17.02 11.39 8.35 1.44 2.85 0.62 0.25 1.96 1.57 3.96 100.51Latvia
36 21 194 405 36 31 202 3 217 8 17 70 445 261 212 61 102 21 5 63 41 97 2901
1.80 0.78 6.51 10.08 1.28 1.43 5.10 0.37 5.79 0.62 0.66 1.57 15.92 10.46 7.57 0.79 2.57 0.35 0.33 1.73 1.30 3.10 92.64Lithuania
60 31 269 494 59 61 243 10 246 16 23 77 571 359 282 53 123 22 8 94 61 115 3784
1.62 1.12 2.31 8.50 1.17 0.78 4.69 . 12.42 . 1.61 0.58 17.08 3.94 5.04 0.91 1.71 0.21 . 1.84 1.28 2.23 78.10Luxembourg
7 7 16 65 9 5 34 . 79 . 9 4 93 22 35 8 11 3 . 18 9 16 519
0.80 0.37 5.72 10.20 4.23 0.88 4.41 0.50 9.34 0.52 0.33 2.34 16.04 7.78 4.26 1.46 1.48 0.63 0.40 0.94 0.54 2.81 84.34Macedonia
14 7 109 190 70 18 85 9 159 10 5 43 272 125 73 28 17 12 6 18 10 42 1459
1.57 0.87 2.87 8.31 0.84 1.36 5.57 0.47 8.08 . 0.48 0.37 15.12 3.86 7.36 1.15 2.23 0.72 0.38 2.39 0.93 2.28 76.26Malta
8 5 17 56 6 9 33 2 41 . 3 4 81 20 36 7 11 3 2 13 6 12 427
1.03 2.15 2.12 12.33 1.17 1.05 6.11 0.22 22.70 0.36 0.67 2.08 16.79 3.28 4.90 1.33 2.36 0.23 0.18 2.20 1.51 2.68 99.41Netherlands
224 471 466 2974 233 253 1331 46 4279 52 117 411 3271 668 1013 333 530 61 32 545 380 565 21066
Norway 0.82 0.84 1.75 11.80 1.30 0.79 5.70 0.17 17.31 0.20 0.67 2.65 10.32 3.82 5.70 1.01 1.35 0.39 0.09 2.04 1.91 1.90 80.90
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Skin Breast Uterus Ovary Bladder Kidney
Thyr
oid HL NHL MM Leukemias
All 
neoplasms
54 56 121 839 81 55 385 10 984 8 33 155 585 218 299 82 99 29 6 140 134 127 5098
1.56 0.72 3.85 11.15 0.64 2.47 5.03 0.50 17.96 0.34 0.69 2.34 14.75 7.92 7.02 1.46 2.22 0.37 0.20 2.06 1.36 2.80 103.31Poland
676 316 1860 5812 290 1214 2440 205 7484 125 233 1408 6319 3443 2785 815 1068 201 73 915 681 1264 47281
0.73 0.43 5.72 9.57 1.40 0.92 3.89 0.15 7.23 0.57 0.53 1.12 12.46 4.28 2.58 1.13 0.70 0.35 0.19 2.34 1.23 2.65 70.77Portugal
107 79 937 1717 229 165 670 18 982 62 64 204 1690 607 351 268 136 68 22 392 236 404 10981
1.11 0.34 5.20 11.45 0.68 0.71 4.86 0.15 5.83 1.17 0.38 1.54 17.49 9.15 4.50 1.01 1.38 0.56 0.48 2.41 0.50 2.59 86.65Rep. of 
Moldova 33 13 167 373 21 24 155 5 184 22 9 50 524 260 123 36 41 15 13 57 16 60 2575
1.43 0.54 4.37 9.88 1.33 1.12 5.06 0.27 10.35 0.79 0.48 1.87 15.67 11.92 5.11 1.08 1.31 0.36 0.19 1.66 0.83 3.33 93.52Romania
305 128 1125 2613 324 276 1286 58 2303 155 95 445 3433 2274 1071 342 345 100 33 330 191 566 21048
1.23 0.74 7.90 12.10 2.33 . 4.69 0.17 5.57 . . 1.32 15.68 9.65 5.50 0.71 . . . 1.32 0.82 2.87 89.09Russia
1823 1320 13509 21276 3951 . 8022 248 8945 . . 1855 22890 13170 7713 1417 . . . 1903 1237 3499 136773
1.20 0.72 3.51 10.85 0.81 1.83 5.61 0.46 18.24 0.50 0.41 2.03 20.17 9.77 6.07 1.51 2.02 0.38 0.48 1.81 0.98 2.76 108.57Serbia
97 59 316 1039 73 182 516 41 1449 33 30 200 1693 741 459 160 173 33 29 157 91 216 9233
1.65 0.66 4.61 14.05 1.32 3.49 6.34 0.19 10.10 0.59 0.77 2.39 15.49 8.65 6.15 1.25 2.88 0.45 0.40 3.10 1.67 3.32 100.65Slovakia
89 37 285 917 74 230 394 10 567 25 31 149 898 469 329 91 191 30 16 195 104 198 5982
0.84 0.59 3.94 10.50 2.81 1.68 5.78 0.36 14.24 0.37 0.71 2.88 15.54 5.69 6.51 1.19 1.74 0.14 0.27 3.34 1.84 2.32 93.51Slovenia
24 14 128 350 93 51 182 9 356 6 18 76 428 162 156 50 57 9 5 133 60 78 2738
0.93 0.50 3.04 8.67 1.82 0.90 4.47 0.19 8.73 0.30 0.60 1.11 10.85 3.83 3.67 1.04 1.25 0.27 0.17 1.69 1.15 2.58 67.57Spain
592 305 2175 6692 1348 744 3095 86 4366 136 281 759 6235 2269 1979 939 906 205 99 1233 928 1589 43705
0.87 0.81 1.68 9.70 1.20 2.13 6.66 0.04 14.44 0.15 0.76 1.86 11.78 4.28 4.50 1.03 1.79 0.26 0.08 1.82 1.56 2.26 82.32Sweden
117 113 219 1474 156 300 940 7 1813 14 79 222 1423 522 553 197 262 44 16 307 242 353 11226
1.20 1.01 1.67 7.15 1.96 0.76 5.56 0.12 12.39 0.29 0.86 1.73 13.51 2.80 4.43 1.13 1.23 0.26 0.12 1.97 1.49 2.36 72.13Switzerland
121 112 198 883 200 91 668 13 1186 21 76 186 1424 299 460 154 155 35 9 261 194 263 7977
0.91 0.37 5.46 9.87 1.32 . 3.60 0.09 4.24 . . 1.38 15.37 9.50 5.23 0.51 . . . 1.29 0.70 2.91 77.36Ukraine
428 173 2707 5268 655 . 1920 41 2109 . . 570 6832 3937 2170 291 . . . 548 316 1025 35012
1.21 2.66 1.72 9.98 2.16 0.64 5.11 0.23 19.86 0.29 0.70 1.58 15.15 4.22 5.25 1.59 1.96 0.28 0.22 2.43 1.35 2.27 93.81UK
913 2494 1581 9375 1930 588 4472 175 16357 138 411 1264 11470 3102 4067 1708 1677 254 152 2243 1360 1940 78972
1.16 2.59 1.62 9.86 2.09 0.62 5.13 0.22 19.05 0.30 0.72 1.59 15.12 4.10 5.23 1.54 1.90 0.29 0.21 2.39 1.34 2.27 92.31UK, Engl and 
Wales 779 2172 1341 8224 1662 513 3976 144 13946 126 369 1130 10190 2682 3587 1482 1453 230 129 1974 1206 1714 69050
1.50 2.50 2.87 10.48 2.49 0.50 4.92 0.20 21.79 . 0.49 1.60 15.59 4.01 5.62 1.09 1.94 0.23 0.24 2.61 1.30 2.63 96.82UK, Northern 
Ireland 27 58 60 246 57 15 112 4 439 . 9 34 291 74 117 33 45 5 5 63 41 61 2062
1.59 3.33 2.35 11.06 2.73 0.87 4.93 0.40 27.44 0.23 0.64 1.46 15.36 5.51 5.28 2.21 2.60 0.24 0.28 2.72 1.39 2.14 108.12UK, Scotland
107 264 180 905 211 60 384 27 1972 12 33 100 989 346 363 193 179 19 18 206 113 165 7860
1.23 1.02 2.91 9.40 1.65 1.24 5.53 0.24 14.28 0.34 0.66 1.47 14.54 4.84 4.78 1.17 1.79 0.29 0.19 2.01 1.24 2.63 85.68EU-28
7785 7474 22162 77122 12329 10023 42201 1402 88502 1580 3430 10764 93903 29691 30213 10900 14039 2370 1075 15945 10294 19137 603984
aAvailable year for Russia and Macedonia: 2013; for Belarus, Bulgaria and Slovakia: 2014.
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 Figure 1. Joinpoint analysis of trends in age-standardized (world population) mortality rates from 23 cancer 
sites and all neoplasms (malignant and benign) in the European Union, from 1990 to 2015. Filled boxes 
represent men, all ages; empty boxes men, 35-64 age group; filled circles women, all ages; empty circles 
women, 35-64 age group. 
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 Figure 2. Joinpoint analysis of trends in age-standardized (world population) mortality rates from all 
neoplasms (a), cancers of intestines (b), lung (c), breast (d) and prostate (e), in 24 selected European 
countries, from 1990 to 2017 (according to data availability). Filled boxes represent men, all ages; empty 
boxes men, 35-64 age group; filled circles women, all ages; empty circles women, 35-64 age group. 
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 Figure 2. Joinpoint analysis of trends in age-standardized (world population) mortality rates from all 
neoplasms (a), cancers of intestines (b), lung (c), breast (d) and prostate (e), in 24 selected European 
countries, from 1990 to 2017 (according to data availability). Filled boxes represent men, all ages; empty 
boxes men, 35-64 age group; filled circles women, all ages; empty circles women, 35-64 age group. 
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